Lucira Health Inc. Common Stock
(NASDAQ:LHDX)
Description
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
LHDX Overview
None
Sector |
Health Care |
Industry |
Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Previous Close |
$18.2700 |
Previous Close Volume |
306693 |